IRLAB has received scientific advisory board confirmation on next steps for pirepemat
Gothenburg, Sweden, February 20, 2026. IRLAB Therapeutics (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that its scientific advisory board has provided important guidance on the continued development and plans for its drug candidate, pirepemat. The advisory board concludes that the pharmacological rationale for pirepemat is sensible and that the reduction in falls observed in the Phase IIb trial is clinically meaningful, warranting further development.
Read More >
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat and reduce risk of falling and falls in Parkinson’s disease.
Q&A session with Kristina Torfgård, CEO and Nicholas Waters, EVP, Head of R&D, at Redeye Technology & Life Science Day
Kristina Torfgård, CEO, and Nicholas Waters, EVP, Head of R&D, participated in the Redeye Technology & Life Science Day on December 3, 2025. https://www.redeye.se/video/event-presentation/1130614/irlab-therapeuti%E2%80%A6-2025-october-15?embed
Read More >